G.R. expresses interest in the selegeline patch, but her insurance company is not willing to approve the nonformulary use of this product and she is unable to afford its monthly cost. Consequently, phenelzine is restarted at a dose of 30 mg daily (15 mg in the morning and at lunchtime). G.R. is being monitored closely for suicidal ideation, especially because the MAOIs are potentially lethal when taken in overdose. What other adverse effects of the nonselective MAOIs should G.R. be monitored for while she is being treated with phenelzine?
